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Recruitment of the K63-linkage specific deubiquitinating enzyme AMSH is an important step in ESCRT-
dependentmembrane protein sorting. In this issue of Structure, Solomons et al. now reveal an extraordinarily
high affinity complex between the ‘‘MIM4’’ region of one ESCRT-III subunit, CHMP3, and the MIT domain of
AMSH.There are times when a cell must deci-
sively get rid of some receptor, transpor-
ter, or other plasma membrane protein.
The major means of disposal involves
the ubiquitination of these proteins and
their sorting into the multivesicular body
(MVB) pathway (Hurley and Stenmark,
2011). MVBs are endosomes that contain
intralumenal vesicles (ILVs). MVBs fuse
with lysosomes, leading to the hydrolysis
of their contents. Ubiquitination is the
main signal that directs membrane pro-
teins into MVBs (Hurley and Stenmark,
2011; Shields and Piper, 2011). Often,
ubiquitination is carried out by members
of the Nedd4 family of ubiquitin ligases
(Hurley and Stenmark, 2011). The ubi-
quitin (Ub) modifications most com-
monly occur in the form of short K63-
linked chains (Hurley and Stenmark,
2011; Shields and Piper, 2011), though
this type of linkage is not always obligate.
The Ub signal is first detected by the
endosomal sorting complex required for
the transport (ESCRT)-0 complex, which
contains five Ub binding sites and thus
binds avidly to polyUb chains. ESCRT-0
is the most upstream of the ESCRT
complexes, which are conserved from
yeast to humans and are involved in cell
processes, from receptor sorting to cyto-
kinesis to viral budding (Hurley and Han-
son, 2010). Inward budding of the endo-
somal membrane is the job of ESCRT-I
and –II (Hurley and Hanson, 2010).
ESCRT-I and –II also bind to Ub, although
they contain fewer binding sites than
ESCRT-0. ESCRT-II recruits and acti-
vates the ESCRT-III complex, which is
responsible for cleavage of membrane
buds into ILVs (Hurley and Hanson,
2010). Unlike the upstream complexes,ESCRT-III does not bind to Ub. Lastly,
the Vps4-Vta1 complex, a dodecameric
AAA ATPase, binds to ESCRT-III and
disassembles it for reuse.
Deubiquitinating enzymes (DUBs) join
the ligases and the Ub receptors as a third
pillar of the system (Komander et al.,
2009). One role of DUBs is to recycle Ub
and so maintain free Ub pools. Different
DUBs interact with both upstream and
downstream ESCRT components, sug-
gesting that their roles go deeper than
pool replenishment. Much evidence
favors the idea that DUBs have such
deeper roles, yet no individual study has
proved this decisively (Hurley and Sten-
mark, 2011; Shields and Piper, 2011).
Indeed, the putative DUB requirement
can be overridden by fusing a single non-
cleavable and nonextendable Ub moiety,
at least in yeast (Shields and Piper, 2011).
In human cells, the DUBs ubiquitin-
specific protease 8 (USP8) and associ-
ated molecule with the SH3 domain of
STAM (AMSH) are targeted by their Pro-
rich regions to the SH3 domain of the
STAM subunit of ESCRT-0 (Hurley and
Stenmark, 2011; Komander et al., 2009).
USP8 and AMSH action might be impor-
tant for disengaging avidly bound K63-
linked Ub chains from ESCRT-0 for cargo
to be handed off to ESCRT-I and –II.
AMSH is a Zn2+-dependent DUB (Hurley
and Stenmark, 2011; Komander et al.,
2009) whose exquisite specificity for
K63-linked Ub chains is hard-wired into
its structure (Sato et al., 2008). Both
AMSH and USP8 contain N-terminal MIT
domains, which target them to ESCRT-III
(Hurley and Stenmark, 2011; Komander
et al., 2009). Thus, these DUBs act at
multiple points in the ESCRT pathway. InStructure 19, August 10, 2011 ªaddition to releasing free Ub at the last
possible moment before cargo is com-
mitted to the lysosome hydrolysis, DUB
action at this late stage might disengage
cargo from ESCRT-I and –II. Indeed, we
still do not know what is the driving force
for cargo migration from the ESCRT-0
coat to the ESCRT-I-II assembly, and
finally into the forming bud. It is tempting
to speculate that DUBs could be involved.
The potential for DUBs to give direc-
tionality to cargo sorting highlights the
importance of the timing of their recruit-
ment. This brings us to MIT domains.
Their best-characterized function is to
bind to the C termini of ESCRT-III sub-
units. These C-terminal tails are seques-
tered in soluble ESCRT-III monomers
and are exposed upon the polymerization
of ESCRT-III into a complex. Both sub-
units of the Vps4-Vta1 disassembly ma-
chine contain MIT domains, which are
their main points of contact with their
ESCRT-III substrate. Canonical MIT
domains are three-helix bundles. Vps4
binds to a C-terminal helical segment,
now termed ‘‘MIM1’’ for MIT-interacting
motif 1, found in the ESCRT-III subunits
CHMP1, 2, and 3. The MIM1 binds with
10 s of mM affinity to the groove between
the second and third a helices of the MIT
domain (Obita et al., 2007; Stuchell-Brer-
eton et al., 2007). This interaction relies
on hydrophobic interactions with ex-
posed Leu residues along a spine of the
MIM1, as well as charged interactions
with MIM1 Arg residues. To complicate
matters, the Vps4 MIT contains a binding
site between its first and third helices for
the C termini of CHMP4 (weak) and
CHMP6, which binds in an extended con-
formation (Kieffer et al., 2008). Moreover,2011 Elsevier Ltd All rights reserved 1033
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Figure 1. A Speculative Model for the Role of the AMSH-CHMP Interaction in Ubiquitinated Cargo Sorting
(A) Key to human ESCRT-III subunits. Subunits are shown according to the order of assembly demonstrated for their yeast orthologs. The precise order of
assembly in human cells is not known.
(B) At an early stage in ESCRT-III assembly, ESCRT-II is shown promoting the polymerization of CHMP6, followed by CHMP4A/B/C. At this stage, ubiquitinated
cargo (here, a heptahelical receptor, in red) might be trapped at the neck of the nascent bud by interactions between the attached K63-Ub chain and the Ub
binding domains of ESCRT-I and -II.
(C) CHMP3 is thought to be the third subunit to assemble into the complex, by analogy with its yeast ortholog. CHMP3 binding to the membrane and to other
subunits releases its C-terminal MIM (shown as a crescent shape). This binds to the MIT domain of AMSH and recruits it to the growing assembly. It is possible
(though not shown here) that additionalmolecules of AMSH could be recruited byCHMP1 (or even byCHMP1 instead of CHMP3) using a distinct lower affinity site
on the MIT domain, or that CHMP3 and CHMP1 could cooperate in recruiting AMSH.
(D) The catalytic JAMM domain of AMSH cleaves the K63-Ub chain and allows the cargo protein to disengage from ESCRT-I and -II and be released into the
nascent bud. ESCRT-I and -II are free to disassociate at this stage. With cargo now removed from the bud neck, ESCRT-III assembly can finish and close
the neck of the bud, leading to membrane scission and ILV release into the lumen of the MVB.
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Previewsthe microtubule-severing enzyme spas-
tin, which coordinates microtubule and
membrane severing in cytokinesis, binds
to an N-terminally extended helical MIM1
but uses the a1/a3 groove to do so in-
stead of the canonical a2/a3 groove
(Yang et al., 2008). Spastin MIT has
a tighter specificity than Vps4 in that it
only binds CHMP1B and IST1, another
ESCRT-III subunit. The restriction is
achievedwith additional steric constraints
requiring small residues N-terminal to the
canonical Leu residues of MIM1. Several
other MIT structures have been deter-
mined, including that of USP8, but, in the
absence of complexation with CHMPs,
they have been less informative.
The article in this issue by Solomons
et al. (2011) is an important addition to
the field, as the first for a DUB in complex
with a CHMP, and the highest affinity
MIT-CHMP complex solved to date. Con-
sisting of five helices, AMSH-MIT is bigger
than the canonical MIT domains of Vps4
and spastin, but similar to the N-terminal
domain of USP8. Helices a2, a3, and the
N-terminal part of a5 correspond to
helices 1–3 of the canonical MIT domains.
The CHMP3 extended MIM1 (or ‘‘MIM4’’)
binds to the counterpart of the MIM1
binding site of Vps4. The affinity of
AMSH-MIT for CHMP3 is extraordinarily
high, in the tens of nM. Additional hy-
drogen bonds with two N-terminal Glu1034 Structure 19, August 10, 2011 ª2011 Eresidues, unique to CHMP3, seem to
contribute to the higher affinity. Various
reports in the field have consistently found
a strong interaction between CHMP3 and
AMSH, but have diverged with respect to
interactions with other CHMPs. This study
confirms the reports that CHMP1 also
binds to AMSH-MIT, but with a far lower
affinity, explaining the less consistent
findings on CHMP1 binding in previous
studies.
The MIT-MIM recognition code now
appears more complex than ever, and
Table 2 in the study by Solomons et al.
(2011) provides a nice summary of the
current stage of knowledge. These are
details that have been discovered one
MIT at a time, by careful structural anal-
ysis. The MIT family is so divergent in
sequence and recognition space that it
has so far not been possible to make
useful predictions about specificity from
homology modeling. At least one more
set of MIT:CHMP complexes, for the
Vta1 subunit of the disassembly complex,
is urgently needed to complete a basic
outline of the code. With such a code in
hand, the next goal will be to have
a more refined understanding of the order
of assembly and action of ESCRT-III
subunits. Based on data coming mainly
from yeast, it is currently thought that
assembly occurs in the order: CHMP6 >
CHMP4 > CHMP3 > CHMP2 > CHMP1 =lsevier Ltd All rights reservedCHMP5 = IST1. This scheme is admittedly
an oversimplification of the complex
picture in mammalian cells. In vitro stu-
dies of MVB biogenesis by yeast ESCRTs
suggest membrane scission could occur
as early as the end of the CHMP3 stage.
On the other hand, mammalian live cell
imaging studies suggest scission might
occur later that this in HIV budding and
cytokinesis. As a rough outline though, it
suggests that AMSH begins to be re-
cruited before the assembly of ESCRT-III
is complete and certainly prior to mem-
brane scission. This model fits well with
the concept that AMSH could have a
role in disengaging cargo from ESCRT-I
and –II so as to facilitate its release
into ILVs.
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High-resolution X-ray crystallography and NMR studies by Koharudin and Gronenborn in this issue provide
new information on the mode of N-glycan recognition by a cyanobacterial agglutinin, with anti-HIV activity
pointing to the pentamannosyl core as a novel target for therapeutic intervention.In addition to its extreme genetic vari-
ability, the human immunodeficiency virus
(HIV) has evolved a number of biological
features that contribute to its notorious
ability to escape from both the innate
and adaptive immune responses. Notable
among these is the extensive glycosylation
of its major envelope glycoprotein gp 120
(120kDa), which is required for HIV infec-
tion that is mediated through interactions
with the glycoprotein CD4 on the surface
of target cells. Approximately fifty percent
of the molecular mass of gp 120 is carbo-
hydrate in the form of diverse N-glycans
(Mizuochi et al., 1988; Feizi and Larkin,
1990). Both on the natural gp120 isolated
from virus-infected lymphocytes and on a
recombinant form of the glycoprotein ex-
pressed in Chinese hamster ovary cells,
a considerable proportion of the glycans
were found to be of the oligomannose
(also termedhigh-mannose) type,whereas
the repertoire of complex-type N-glycans
was cell-type specific. The conservation
of a large population of oligomannose
N-glycans has now been confirmed in
primary isolates from geographically
diverse clades of HIV that have been pro-
duced from the direct infection of human
cells (Bonomelli et al., in press).When the observations of the heavy
glycosylation of gp 120 were first made,
we wondered whether the glycans served
to camouflage the virus in the infected
host or whether they had an influence at
particular stages of the infection process
(Feizi and Larkin, 1990). Indeed, there is
an enormous body of evidence on the
way that glycans serve to shield the gp
120 polypeptide from immune attack;
however, this topic is beyond the scope
of this commentary. We focus here on
the oligomannose N-glycans, which have
proven to be more than merely shields in
the armamentarium of the virus! HIV uses
its oligomannose N-glycans to highjack
akeyprotein of the innate immunesystem,
DC-SIGN, and gain entry into a protected
environment in dendritic cells, where
they remain available and poised to reach
the cell surface to infect bystander
T-lymphocytes (Geijtenbeek et al., 2000).
As for the host’s immune response
toward the gp 120N-glycans, interactions
with two of the innate immune proteins,
mannose-binding protein and the macro-
phage receptor, have been observed
in vitro, but a clear picture has not
emerged with regard to any protective
effects they might have in infectedpatients. An unpredicted development
has been the discovery, among broadly
neutralizing antibodies against HIV, of an
antibody, clone 2G12, which is directed
at the Mannose-9 (Man9) N-glycan (Scan-
lan et al., 2002). This antibody requires the
Mana1-2Man termini of its D1 arm
(Dunlop et al., 2010) (Figure 1A). These
findings have served to stimulate efforts
in two directions. The first is ongoing
studies to develop vaccination strategies
to generate anti-Man9 antibodies with
broadly neutralizing activities, such as
those described by Dunlop et al. (2010).
The second direction has been to estab-
lish technologies to map the specificities
of broadly neutralizing antibodies in sera
of patients that exhibit the most potent
antiviral activities (Walker et al., 2010).
There are encouraging indications with
regard to the natural occurrence of anti-
bodies, which are either directed to
protein structures dependent on N-linked
glycosylation or, as for 2G12, directly bind
to the glycans of gp120. Further develop-
ments are eagerly awaited.
Bacterial, fungal, and algal proteins
with potent antiviral activities have now
‘‘emerged’’ in the anti-HIV battlefield and
exhibit great potential applications as2011 Elsevier Ltd All rights reserved 1035
